SCHEMBL2486503

SCHEMBL2486503

CC(=O)Nc1cccc(-c2n[nH]c3ncc4c(c23)CCN(C(=O)OC(C)(C)C)C4)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 4/20 0.41
TTK P33981 2/20 0.41
MAPK8 P45983 2/20 0.41
MAPT P10636 2/20 0.40
PARP1 P09874 1/20 0.40
TNKS2 Q9H2K2 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
UCHL1 P09936 1/20 0.39
LRRK2 Q5S007 1/20 0.39
ESR2 Q92731 1/20 0.39
PDE5A O76074 1/20 0.39
PDE1A P54750 1/20 0.39
PDE1B Q01064 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE1C Q14123 1/20 0.39
PDE3A Q14432 1/20 0.39
PAK1 Q13153 1/20 0.38
NR1H2 P55055 1/20 0.38
FGFR3 P22607 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2487772 0.87 CKS1B (0.46) MAPTPARP1TNKS2PARP2UCHL1
SCHEMBL2485087 0.86 NR1H2 (0.41) MKNK1TTKMAPK8MAPTPARP1
SCHEMBL2802667 0.83 NR1H2 (0.38) MKNK1MAPTPARP1TNKS2PARP2
SCHEMBL2484168 0.83 NAMPT (0.39) MKNK1MAPTPARP1TNKS2PARP2
SCHEMBL2487072 0.79 PARP1 (0.45) MKNK1MAPTPARP1TNKS2PARP2
SCHEMBL2488516 0.78 BTK (0.40) MKNK1TTKMAPK8PARP1TNKS2
SCHEMBL2487129 0.77 MAPT (0.46) MKNK1MAPTPARP1TNKS2PARP2
SCHEMBL2805911 0.77 TTK (0.45) TTKMAPK8MAPTPARP1LRRK2
SCHEMBL2483733 0.77 NAMPT (0.58) NAMPT
SCHEMBL2805115 0.76 NPC1 (0.53) NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
EP-2379551-A1 SUBSTITUTED PYRAZOLO [3, 4-B]PYRIDINE COMPOUNDS ArQule, Inc. (US) 2011-10-26 EP disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 MKNK1 1446/4885TTK 3440/4885MAPK8 2818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.